BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1256 related articles for article (PubMed ID: 27222021)

  • 1. Update on advances in molecular PET in urological oncology.
    Kitajima K; Yamamoto S; Fukushima K; Minamimoto R; Kamai T; Jadvar H
    Jpn J Radiol; 2016 Jul; 34(7):470-85. PubMed ID: 27222021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDG in Urologic Malignancies.
    Høilund-Carlsen PF; Poulsen MH; Petersen H; Hess S; Lund L
    PET Clin; 2014 Oct; 9(4):457-68, vi. PubMed ID: 26050947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positron-emission tomography imaging in urological oncology: Current aspects and developments.
    Rauscher I; Eiber M; Weber WA; Gschwend JE; Horn T; Maurer T
    Int J Urol; 2018 Nov; 25(11):912-921. PubMed ID: 30103285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
    Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
    Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of positron emission tomography in urological oncology.
    Rioja J; Rodríguez-Fraile M; Lima-Favaretto R; Rincón-Mayans A; Peñuelas-Sánchez I; Zudaire-Bergera JJ; Parra RO
    BJU Int; 2010 Dec; 106(11):1578-93. PubMed ID: 21078036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PET/MRI with diagnostic MR sequences vs PET/CT in the detection of abdominal and pelvic cancer.
    Xin J; Ma Q; Guo Q; Sun H; Zhang S; Liu C; Zhai W
    Eur J Radiol; 2016 Apr; 85(4):751-9. PubMed ID: 26971419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive Oncologic Imaging in Infants and Preschool Children With Substantially Reduced Radiation Exposure Using Combined Simultaneous ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Imaging: A Direct Comparison to ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
    Gatidis S; Schmidt H; Gücke B; Bezrukov I; Seitz G; Ebinger M; Reimold M; Pfannenberg CA; Nikolaou K; Schwenzer NF; Schäfer JF
    Invest Radiol; 2016 Jan; 51(1):7-14. PubMed ID: 26309185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET)/MRI for Lung Cancer Staging.
    Ohno Y; Koyama H; Lee HY; Yoshikawa T; Sugimura K
    J Thorac Imaging; 2016 Jul; 31(4):215-27. PubMed ID: 27075745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of FDG PET/MRI and FDG PET/CT in Pediatric Oncology in Terms of Anatomic Correlation of FDG-positive Lesions.
    Uslu-Beşli L; Atay Kapucu LÖ; Karadeniz C; Akdemir ÜÖ; Pinarli FG; Aydos U; Okur A; Kaya Z; Samanci C; Karabacak NI
    J Pediatr Hematol Oncol; 2019 Oct; 41(7):542-550. PubMed ID: 30933019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical advances of fluorine-2-D-deoxyglucose--positron emission tomography/computed tomography in urological cancers.
    Avril N; Dambha F; Murray I; Shamash J; Powles T; Sahdev A
    Int J Urol; 2010 Jun; 17(6):501-11. PubMed ID: 20370848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular positron emission tomography and PET/CT imaging in urological malignancies.
    Powles T; Murray I; Brock C; Oliver T; Avril N
    Eur Urol; 2007 Jun; 51(6):1511-20; discussion 1520-1. PubMed ID: 17275167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Why is PET/CT essential in urooncology?].
    Borbély K; Géczi L; Kásler M
    Magy Onkol; 2013 Dec; 57(4):282-96. PubMed ID: 24353995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PET/MRI of the breast.
    Plecha DM; Faulhaber P
    Eur J Radiol; 2017 Sep; 94():A26-A34. PubMed ID: 28549570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nuclear medicine in urological cancers: what is new?
    Nanni C; Zanoni L; Fanti S
    Future Oncol; 2014 Oct; 10(13):2061-72. PubMed ID: 25396777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pivotal role of FDG-PET/CT in modern medicine.
    Hess S; Blomberg BA; Zhu HJ; Høilund-Carlsen PF; Alavi A
    Acad Radiol; 2014 Feb; 21(2):232-49. PubMed ID: 24439337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
    Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A
    J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
    Schaefferkoetter JD; Carlson ER; Heidel RE
    J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [PET-FDG in metastases from urological malignancies].
    Labarthe P; Méjean A; Lebret T
    Prog Urol; 2008 Nov; 18 Suppl 7():S208-12. PubMed ID: 19070793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update of the role of PET/CT and PET/MRI in the management of patients with cervical cancer.
    Khiewvan B; Torigian DA; Emamzadehfard S; Paydary K; Salavati A; Houshmand S; Shamchi SP; Werner TJ; Aydin A; Roy SG; Alavi A; Kumar R
    Hell J Nucl Med; 2016; 19(3):254-268. PubMed ID: 27824966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. (18)F-Fluorodeoxyglucose PET/MR Imaging in Head and Neck Cancer.
    Platzek I
    PET Clin; 2016 Oct; 11(4):375-86. PubMed ID: 27593244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 63.